Yttrium-90
Yttrium-90 is a radiation therapy with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
3
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90Yttrium Colloid
Clinical Trials (5)
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90Yttrium Colloid
All 5 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 5